Scholar Rock Revenue and Competitors

Claim your profile

Boston, MA USA

Location

$153M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Scholar Rock's estimated annual revenue is currently $18.2M per year.(i)
  • Scholar Rock received $47.0M in venture funding in January 2018.
  • Scholar Rock's estimated revenue per employee is $111,656
  • Scholar Rock's total funding is $153M.
  • Scholar Rock's current valuation is $710.2M. (January 2022}

Employee Data

  • Scholar Rock has 163 Employees.(i)
  • Scholar Rock grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Scholar Rock® is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

keywords:Biotechnology,Healthcare,Healthcare Providers,Pharmaceuticals

$153M

Total Funding

163

Number of Employees

$18.2M

Revenue (est)

12%

Employee Growth %

$710.2M

Valuation

N/A

Accelerator

Scholar Rock News

2018-01-03 - Scholar Rock Raises $47M in Series C Financing

Scholar Rock, a Cambridge, Mass.-based biotechnology company focused on discovering and developing drugs that selectively modulate growth factor activation in the disease microenvironment, closed a $47m Series C financing. The round was led by new investor Invus, with participation from new inv ...

2021-06-14 - SCHOLAR ROCK HOLDING CORPORATION Scholar Rock : Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an oral presentation of TOPAZ Phase 2 trial results by the lead principal investigator, Thom ...

2021-09-29 - Scholar Rock : Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGF 1 Activation

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,130,803, ...

09/03/2019 - Scholar Rock Announces Appointment of George Nomikos ...

Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise.

09/08/2019 - Scholar Rock to Present at Upcoming Healthcare Conferences

CAMBRIDGE, Mass., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical ...

09/03/2019 - Scholar Rock Announces Upcoming Departure of Chief ...

CAMBRIDGE, Mass., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (Nasdaq: SRRK), a clinical stage ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A16312%N/A
#2
$4.5M16431%$173.3M
#3
$18.4M164-4%N/A
#4
$33.2M165-4%N/A
#5
$25.6M16567%$454M

Scholar Rock Funding

DateAmountRoundLead InvestorsReference
2014-09-16$20.0MAARCH Venture PartnersArticle
2016-01-05$36.0MBFidelity Management and Research CompanyArticle
2018-01-04$47.0MCInvusArticle